Scholarlink

<p>Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of <i>SRSF2</i> mutations on erythropoiesis. We found reduced erythropoiesis in <i>Srsf2</i><sup>P95H</sup> versus wild-type mice upon stress-induced erythropoiesis and identified that <i>SRSF2</i> mutations correlate with reduced hemoglobin in <i>JAK2</i>-mutant patients with myeloproliferative neoplasms (MPN). Consistent with this, <i>Jak2</i><sup>V617F</sup><i>-Srsf2</i><sup>P95H</sup> versus <i>Jak2</i><sup>V617F</sup> mice displayed reduced red blood cell counts and erythroid precursor frequencies. RNA-sequencing on erythroid precursors showed reduced expression of heme metabolism and mitotic spindle-related genes, and increased expression of mTORC1 signaling in <i>Srsf2</i><sup>P95H</sup> versus wild-type cells. RNA splicing analyses on the same cells and on human patient samples identified aberrant FYN splicing in SRSF2<sup>mut</sup> cells, with increased aberrant FYNB over normal FYNT transcripts. FYNB, but not FYNT, expression resulted in reduced erythroid differentiation and increased phosphorylation of mTORC1 downstream target S6. Additionally, increased S6 phosphorylation was confirmed in primary <i>Srsf2</i><sup>P95H</sup> erythroid cells. mTORC1 pathway inhibition using rapamycin normalized FYNB- and <i>Srsf2</i><sup>P95H</sup>-induced impaired erythropoiesis and significantly increased erythroid colony formation of <i>SRSF2</i>-mutant myelodysplastic neoplasm (MDS) bone marrow cells. Our data reveal targetable molecular mechanisms of impaired erythropoiesis in <i>SRSF2-</i>mutant cells.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing

  • 期刊论文

  • 发表日期：

    2026年2月26日

查看全文
  • Jonas S. Jutzi,
  • Edie Crosse,
  • Chulwoo J. Kim,
  • Bob van Gasteren,
  • Charles Laurore,
  • Benjamin Rolles,
  • Frederike Kramer,
  • Anastasia Tishena,
  • Azucena V. Rocha,
  • Mohammed Wazir,
  • Lachelle D. Weeks,
  • Joan How,
  • Maximilian Stahl,
  • Marlise R. Luskin,
  • R. Coleman Lindsley,
  • Olga Pozdnyakova,
  • Sumit Rai,
  • Timothy A. Graubert,
  • Robert K. Bradley,
  • Ann Mullally,
  • Anna E. Marneth

摘要

Somatic mutations in RNA splicing regulators, including the serine/arginine-rich protein SRSF2, are frequently observed in myeloid malignancies. Using mouse models and primary human samples, we investigated the impact of SRSF2 mutations on erythropoiesis. We found reduced erythropoiesis in Srsf2P95H versus wild-type mice upon stress-induced erythropoiesis and identified that SRSF2 mutations correlate with reduced hemoglobin in JAK2-mutant patients with myeloproliferative neoplasms (MPN). Consistent with this, Jak2V617F-Srsf2P95H versus Jak2V617F mice displayed reduced red blood cell counts and erythroid precursor frequencies. RNA-sequencing on erythroid precursors showed reduced expression of heme metabolism and mitotic spindle-related genes, and increased expression of mTORC1 signaling in Srsf2P95H versus wild-type cells. RNA splicing analyses on the same cells and on human patient samples identified aberrant FYN splicing in SRSF2mut cells, with increased aberrant FYNB over normal FYNT transcripts. FYNB, but not FYNT, expression resulted in reduced erythroid differentiation and increased phosphorylation of mTORC1 downstream target S6. Additionally, increased S6 phosphorylation was confirmed in primary Srsf2P95H erythroid cells. mTORC1 pathway inhibition using rapamycin normalized FYNB- and Srsf2P95H-induced impaired erythropoiesis and significantly increased erythroid colony formation of SRSF2-mutant myelodysplastic neoplasm (MDS) bone marrow cells. Our data reveal targetable molecular mechanisms of impaired erythropoiesis in SRSF2-mutant cells.